PSA Velocity in Risk Stratification of Prostate Cancer.
Year: 2013
Type: article
Abstract: Since the introduction of widespread prostate-specific antigen (PSA)-based prostate cancer screening, several markers have been employed to aid in detection of prostate cancer. The change in PSA level over time, PSA velocity (PSAV), is such a marker that may improve specificity; however, its role as an adjunct to PSA is controversial. Some prior studies have shown that a PSAV provides independent predictive information for estimating prostate cancer risk1 and a PSAV threshold of 0.35 to 0.4 ng/mL/year has been associated with the likelihood of insignificant prostate cancer, suggesting that PSAV may increase specificity for identifying patients with clinically significant disease.2,3 Conversely, other studies have shown that PSAV has limited value4 and biopsying men with high PSAV but no other indication would lead to a large number of additional prostate biopsies.5 Recently, Orsted and colleagues6 and Wallner and associates7 evaluated the value of PSAV as an adjunct marker to PSA, its role in predicting aggressive disease, and improving classification of prostate cancer risk and mortality.
Source: PubMed Central
Authors: Marc A Bjurlin, Stacy Loeb
Institution: New York University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2409146739